Design and development of a multifunctional nano carrier system for imaging, drug delivery, and cell targeting in cancer research.

摘要

There has been an increasing need in the last decade for early diagnosis and treatment of cancer prior to the tumor mass becoming evident as anatomical anomaly. A major challenge in cancer diagnosis is to distinguish cancer cells from the surrounding, normal tissue. For early cancer diagnosis and treatment, a nano carrier system was designed and developed with key components uniquely structured according to biomedical and clinical requirements: targeting, drug storage capabilities, fluorescent emissions near the infrared range for in vivo imaging, and magnetic hyperthermia. For in vivo imaging, quantum dots with emissions near infrared range (∼800 nm) were conjugated onto the surface of carbon nanotubes and nanospheres consisting of a spherical polystyrene matrix (∼100 nm) and high fraction of superparamagnetic Fe3O4 nanoparticles (∼10 nm) embedded. The QDs on these nano carriers exhibited intense visible emissions using fluorescent spectroscopy and successfully facilitated in vivo soft tissue imaging in mice. For drug storage, the chemotherapeutic agent, paclitaxel (PTX) was loaded onto the surfaces of these nano-carriers by using a layer of biodegradable poly(lactic-co-glycolic acid) (PLGA). A cell-based cytotoxicity assay was employed to verify successful loading of pharmacologically active drug, PTX. Cell viability of human, metastatic PC3mm2 prostate cancer cells was assessed in the presence and absence of various nano-carrier populations using the MTT assay. For hyperthermia, Fe3O 4 nanoparticles were conjugated onto the surfaces of carbon nanotubes (CNT) and embedded into the nanospheres. Magnetization measurements showed nearly reversible hysteresis curves from the Fe3O4-conjugated CNTs and the magnetic nanospheres (MNS). Application of an alternating electromagnetic field effectively induced heating the solution of the Fe3O 4-conjugated CNTs and the magnetic nanospheres (MNS) into temperature ranges (up to 55ºC) suitable for therapeutic hyperthermia. PTX loaded nanocarrier systems were, then, developed by conjugating anti-Prostate Specific Membrane Antigen (anti-PSMA) for in vitro and in vivo targeting. Specific detection studies of anti- PSMA-conjugated nano carrier systems binding activity in LNCaP prostate cancer cells were carried out. Substantial differences were observed between the targeted- and nontargeted nano carriers. LNCaP cells were targeted successfully by the conjugation of anti- PSMA on the nano carrier surfaces. To explore in vivo targeting, the nano carriers conjugated with anti-PSMA were intravenously injected into nude mice bearing a human prostate cancer cell (LNCaP). Upon post-injection, significant fluorescence attributed to the nano-carrier system was detected, indicating substantial uptake in the region of the tumor.